Peripheral Arterial Disease Clinical Trial
Official title:
Natural Vascular Scaffold (NVS) Therapy for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
Verified date | November 2018 |
Source | Alucent Medical, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The NVS Therapy is being studied to evaluate the safety and efficacy of retention of acute luminal gain, leading to acute hemodynamic improvement in superficial femoral and popliteal arteries with reference vessel diameters between 3.5 and 7.0 mm and lesion lengths between 36 and 96mm. The system is intended for use in patients with de novo lesions in the superficial femoral and proximal popliteal arteries.
Status | Completed |
Enrollment | 3 |
Est. completion date | October 29, 2018 |
Est. primary completion date | October 29, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subject is at least 18 years of age. - Subject (or legal guardian) understands the study requirements and the treatment procedure and provides written informed consent before any study-specific tests or procedures are performed. - Subject is eligible for PTA. - Subject is willing to comply with all protocol required follow-up evaluations. - Subject has documented Rutherford Classification 2 to 4 (see Appendix 3). - Subject has laboratory test results that are within clinically acceptable limits. - In Investigator's opinion, subject is hemodynamically stable at the time of the index procedure. - Subject has a life expectancy of =1 year in the opinion of the Investigator. Exclusion Criteria: - Subject had cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months prior to enrollment. - Subject has any permanent neurologic defect that may cause non-compliance with the protocol. - Subject had an MI within last the 3 months prior to enrollment. - Subject is pregnant, planning to become pregnant, breastfeeding or planning to breastfeed in the next 365 days. - Subject is currently receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded). - Subject has known life-limiting immunosuppressive or autoimmune disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus). - Subject has local or systemic thrombolytic therapy within 48 hours prior to index procedure. - Subject is currently on oral anticoagulation therapy, such as warfarin, rivaroxaban, apixaban, or dabigatran etexilate. - Subject has known allergies or sensitivities to heparin, aspirin (ASA), or other anticoagulant/antiplatelet therapies. - Subject has an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure. - Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding. - Subject has documented or suspected liver disease, including laboratory evidence of hepatitis. - Subject has renal failure or chronic kidney disease with glomerular filtration rate (GFR) = 30 mL/min or Modification of Diet in Renal Disease (MDRD) study equation result of = 30 mL/min per 1.73 m2. - Subject has white blood cell (WBC) count < (3,000 cells/mm3) within 7 days prior to index procedure. - Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 = 7 days pre-procedure. - Subject has been diagnosed with bleeding diatheses or hypercoagulable state. - Subject has known or suspected active systemic infection evidenced by WBC > 14.0 (14,000/mm3). - Subject is currently participating in another investigational drug or device study. - Subject intends to participate in another investigational drug or device study within 365 days after the index procedure. - Subject has any surgical procedure or intervention performed within the 30-day period prior to index procedure. |
Country | Name | City | State |
---|---|---|---|
United States | OhioHealth Research Institute | Columbus | Ohio |
United States | Wellmont CVA Heart Institute | Kingsport | Tennessee |
United States | Lankenau Institute for Medical Research | Wynnewood | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Alucent Medical, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | NVS Drug Plasma Concentrations | The Peak Plasma Concentration (Cmax) will be determined from plasma 10-8-10 Dimer concentrations for blood samples collected. | Day 1 | |
Primary | Freedom from all-cause mortality, target limb major amputation, and target lesion revascularization based on clinical observations | The overall composite occurrence of participants free from from all-cause mortality, target limb major amputation, and target lesion revascularization through post-index procedure to Day 30 will be summarized as a percentage. | Day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |